# Sacubitril + Valsartan

## Entresto 100mg

| TAH Drug Code      | [OENTR](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OENTR)                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Heart failure, chronic. Symptomatic congestive heart failure, In Patients with Systemic Left Ventricular Dysfunction,                                                                                                                                                                         |
| Dosing             | CHF adult, initial 100mg BID, maintain dose: 200mg BID after 2-4 weeks. ( if Entresto switch from ACEI, it must be separated at least 36 hr)                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                 |
| Contraindications  | Angioedema to prior ACE inhibitor or angiotensin II receptor blocker therapy. Concomitant aliskiren use in diabetic patients. Concomitant use of ACE inhibitors; do not administer within 36 hours of each other. Hypersensitivity to sacubitril, valsartan, or any component of the product. |
| Adverse Effects    | Common: Hypotension (18%), Hyperkalemia (12-16%), Dizziness (6%) Serious: Renal failure (5%), Angioedema (0.5%)                                                                                                                                                                               |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information)                                                                                                                                                                                                       |

